User250673

Syneron Medical's Superb Q2 Treatment

CYNO qtly rev growth 30.10% vs ELOS 1.90%. CYNO ROA 10.35% vs ELOS 6.58%. CYNO ROE 16.4% vs ELOS 13.4%. Don't get me wrong, I own both and both are leaders in the industry, but CYNO is clearly outperforming CUTR, CLZR, ELOS, PMTI etc. ELOS hdqt in Israel is a definite risk and their share price is going to stay depressed until there's more stability in the Mid-East no matter how much they sell overseas. ELOS deferred LT liabilities far outweight CYNO minimal debt, not that it changes anything.